FDA CBER outlines how blood centres may reevaluate donors initially reactive for HBsAg

What happened

On 2 November 2026, FDA's Center for Biologics Evaluation and Research (CBER) published recommendations on managing donors and units that are initially reactive for hepatitis B surface antigen (HBsAg). According to the record, the recommendations describe how blood establishments may reevaluate such donors, provided other suitability requirements are met.

The records do not include the document's full text. They do not say whether it is draft or final, what reevaluation steps it sets out, or how it treats the affected units. Those details determine the operational impact, so quality and donor-management teams should read the source document before changing procedures.

Why it matters

HBsAg is a standard marker used in screening donations for hepatitis B virus. An initially reactive screening result is not the same as a confirmed infection, so how a donor and a unit are handled after that result matters both for safety and for donor retention. Any pathway that allows reevaluation, rather than leaving a donor permanently out after a first reactive result, changes the procedures blood establishments need to define and defend.

The wording in the record is conditional: establishments "may" reevaluate donors, and only where other suitability requirements are met. That makes the guidance an option to be built into a procedure, not an obligation. Establishments that adopt it will need documented, validated procedures covering the reevaluation. Those that do not will need to be clear on how their existing practice differs.

Regulatory context: a same-day pairing

The document did not arrive alone. The same day, CBER issued final guidance on hepatitis B testing of blood donations. According to the records, that guidance sets out recommendations for blood establishments, including Source Plasma collectors, on testing donations to reduce the risk of transfusion-transmitted hepatitis B virus.

The records do not state how the two documents cross-refer. Still, their publication together suggests they should be read as a set. The testing guidance addresses what is tested and how the risk is reduced. The HBsAg recommendations address what happens after an initial reactive result. A gap between your testing algorithm and your donor-management procedure is the kind of inconsistency an inspector could raise.

The inclusion of Source Plasma collectors in the testing guidance matters for the plasma sector. Whether the HBsAg reevaluation recommendations apply equally to Source Plasma is not stated in the lead record and should be checked in the document itself.

CBER also finalised its potency assurance guidance for cellular and gene therapy products the same day, superseding the January 2011 potency tests guidance. That document concerns a different product class, but it shows the center updating older quality-related guidance in more than one area at once.

Who is affected

The most directly affected are blood establishments, including those collecting Source Plasma, along with their quality, medical and donor-management functions. Reevaluating donors implicates SOPs, donor records, computer-system rules for deferral and reentry, and staff training.

Plasma derivative manufacturers and other organisations that rely on donations from blood establishments should also understand how their suppliers apply the recommendations. The records do not describe supply-chain effects, and none should be assumed. Regulatory affairs teams at such organisations may nonetheless want to ask suppliers how they plan to apply the new recommendations and whether any change affects supplier qualification or agreements.

Regulatory teams outside blood and plasma have little to act on here. The other 2 November records concern separate matters, including the accelerated approval of Inovio's Voceryq (INO-3107) for recurrent respiratory papillomatosis, FDA's priority review of uniQure's AMT-130 filing with a decision due by 1 May 2027, and the approval of NRx's preservative-free ketamine generic. They are not connected to the donor guidance.

What to watch

Three questions remain open from the records. First, the legal status of the HBsAg document: whether it is final guidance or something still open to comment, which affects how firmly establishments can rely on it. Second, whether FDA will clarify how the reevaluation approach interacts with the new testing guidance, especially for Source Plasma. Third, whether any implementation timeline applies. The records mention none.

Inspection practice will be the real test. How investigators view a reevaluation procedure, and what documentation they expect to see for a donor who was initially reactive and later returned to eligibility, will become clear only through inspections and any follow-up communication from CBER.